Table 6.

Shows synergy in HEPG2 cells with a comparison of dose (synergistic) to current in vivo clinical dose

Chemo agent (in vitro)	In vivo dose (Synergy)	Current clinical dose	% reduction in dose	Bromelain dose (Synergy)	CAP
GEM 0.132 µg/ml	132 µg/kg; 4.88 mg/M2	25 mg/kg; 1000 mg/M2	99.5	15.0 µg/ml (in vitro)	SYS
				15 mg/kg; 555 mg/M2 (in vivo)
5-FU 0.325 µg/ml	325 µg/kg; 12.0 mg/M2	71 mg/kg; 2627 mg/M2	99.54		SYS

CAP = Clinical application; SYS = systemic. It indicates that using the principal of synergy, when combined with suitable dose of bromelain, the requirement for chemotherapeutic agents such as gemcitabine and 5-FU can be dramatically reduced.